injection contains a highly purified
streptokinase derived from cultural filtrate
of beta-hemolytic streptococci of lance
field group C.
The drug is supplied as a sterile,
lyophilized white powder
Each vial contains: streptokinase BP
1,500,000 or 750.000 I.U.
► Acute myocardial infarction.
► Deep vein thrombosis
► Pulmonary embolism
► Acute or sub-acute thrombosis of peripheral arteries
► Chronic occlusive arterial disease
► Occlusion of central retina artery or vein.
► Acute myocardial infarction:
(IV administration) in acute myocardial
infarction 1.5 million I.U of streptokinase
are infused in 60 min. with this regimen
usually no coagulation tests are necessary
to monitor streptokinase therapy.
Treatment should be started as soon as
possible after the onset of symptoms.
Significant reduction in mortality has been
observed with the administration of
streptokinase up to 24 hrs after onset of
However the earlier the treatment is started
the greater the clinical benefit will be in
terms of mortality reduction.
A loading dose of 20,000 I.U,
streptokinase is given as a bolus, followed
by a 30 – 90 min infusion of 2000-4000
► Deep vein
thrombosis, pulmonary embolism and other
Streptokinase treatment should be
instituted as soon as possible after the
thrombotic event. Streptokinase therapy is
to be beneficial if instituted
► In more than
14 days after the onset of deep venous
► 6 -8 hours
after onset of central retinal artery
► 10 days from
onset of central retinal vein thrombosis
► 6 weeks in
chronic arterial occlusions
► An initial
dose of 250,000 I.U streptokinase, by
intravenous infusion over a period of 30 min
is given. Followed by a
maintenance dose of
100,000 I.U per hour for 24 to 72 hrs,
depending on the response.
should not be reinstituted during or
following streptokinase infusion until the
TT or APTT have reached less than
1.5 times the normal control value
Vials each containing 1,500,000 or 750.000 IU
Facts About Streptokinase